Evan Roberts Sells 12,749 Shares of Phreesia, Inc. (NYSE:PHR) Stock

Phreesia, Inc. (NYSE:PHR) COO Evan Roberts sold 12,749 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $27.31, for a total value of $348,175.19. Following the completion of the sale, the chief operating officer now directly owns 755,459 shares of the company’s stock, valued at $20,631,585.29. This represents a 1.66 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Evan Roberts also recently made the following trade(s):

• On Wednesday, January 15th, Evan Roberts sold 1,785 shares of Phreesia stock. The shares were sold at an average price of $26.98, for a total transaction of $48,159.30.
• On Wednesday, January 8th, Evan Roberts sold 2,681 shares of Phreesia stock. The stock was sold at an average price of $27.95, for a total transaction of $74,933.95.
• On Monday, January 6th, Evan Roberts sold 2,873 shares of Phreesia stock. The shares were sold at an average price of $26.61, for a total transaction of $76,450.53.

Phreesia Stock Up 0.2 %

Shares of NYSE:PHR opened at $27.26 on Friday. Phreesia, Inc. has a 12 month low of $17.07 and a 12 month high of $29.16. The firm has a market cap of $1.58 billion, a P/E ratio of -18.55 and a beta of 0.94. The company has a quick ratio of 1.74, a current ratio of 1.74 and a debt-to-equity ratio of 0.04. The company’s 50-day moving average price is $23.87 and its two-hundred day moving average price is $22.97.

Phreesia (NYSE:PHR) last released its quarterly earnings results on Monday, December 9th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.04. Phreesia had a negative net margin of 20.43% and a negative return on equity of 32.78%. The business had revenue of $106.80 million for the quarter, compared to analysts’ expectations of $106.33 million. During the same period in the prior year, the firm earned ($0.58) earnings per share. Phreesia’s revenue was up 16.6% compared to the same quarter last year. As a group, research analysts forecast that Phreesia, Inc. will post -1.1 EPS for the current fiscal year.

Institutional Investors Weigh In On Phreesia

Institutional investors and hedge funds have recently made changes to their positions in the company. R Squared Ltd bought a new position in Phreesia in the fourth quarter valued at about $30,000. International Assets Investment Management LLC lifted its position in Phreesia by 2,179.7% during the 3rd quarter. International Assets Investment Management LLC now owns 1,459 shares of the company’s stock valued at $33,000 after purchasing an additional 1,395 shares during the period. Lombard Odier Asset Management USA Corp bought a new position in shares of Phreesia in the 2nd quarter valued at about $202,000. Point72 DIFC Ltd acquired a new stake in shares of Phreesia during the 2nd quarter worth approximately $209,000. Finally, XTX Topco Ltd bought a new stake in shares of Phreesia during the third quarter worth approximately $247,000. Institutional investors own 92.10% of the company’s stock.

Analysts Set New Price Targets

PHR has been the topic of a number of analyst reports. Truist Financial upped their target price on shares of Phreesia from $31.00 to $34.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Citigroup upped their price objective on Phreesia from $31.00 to $35.00 and gave the company a “buy” rating in a research note on Friday, January 10th. Robert W. Baird cut their target price on Phreesia from $34.00 to $30.00 and set an “outperform” rating for the company in a research report on Wednesday, December 11th. Royal Bank of Canada upgraded Phreesia from a “sector perform” rating to an “outperform” rating and upped their price target for the company from $24.00 to $32.00 in a research report on Wednesday, January 8th. Finally, Needham & Company LLC reissued a “buy” rating and set a $29.00 price objective on shares of Phreesia in a report on Friday, January 10th. Twelve equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $31.00.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.